The prevalence of neural antibodies in temporal lobe epilepsy and the clinical characteristics of seropositive patients

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F18%3A10382702" target="_blank" >RIV/00216208:11130/18:10382702 - isvavai.cz</a>

Alternative codes found

RIV/00064203:_____/18:10382702

Result on the web

<a href="https://doi.org/10.1016/j.seizure.2018.09.009" target="_blank" >https://doi.org/10.1016/j.seizure.2018.09.009</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.seizure.2018.09.009" target="_blank" >10.1016/j.seizure.2018.09.009</a>

Result language

angličtina

Original language name

The prevalence of neural antibodies in temporal lobe epilepsy and the clinical characteristics of seropositive patients

Original language description

PURPOSE: Epileptic seizures are a common manifestation of autoimmune encephalitis, but the role of neural antibodies in long-term epilepsy remains unclear. The aim of this study was to assess the prevalence of neural-surface antibodies (NSAbs) and antibodies against glutamic acid decarboxylase (GAD) in patients with chronic temporal lobe epilepsy (TLE). METHOD: Patients with an electro-clinical diagnosis of TLE and a disease duration longer than one year were included. NSAbs (LGI1, CASPR2, AMPAR1/2, NMDAR, GABA B R) and antibodies against GAD were detected. Only patients with significant antibody levels in serum, and/or positivity in CSF (according to antibody subtype), were enrolled in the seropositive group. Cohorts of seropositive and seronegative patients were compared regarding clinical and imaging data. RESULTS: Significant serum levels of antibodies were detected in eight out of 163 (5%) TLE patients (CASPR2 n = 2, GAD n = 3, LGI1 n = 2, and GABA B R n = 1). In four of them, antibodies were detected in the CSF as well (CASPR2 in one, GAD in three). Five seropositive patients had uni- or bilateral temporal lobe lesions on MRI and three patients were non-lesional. All seropositive patients had TLE of unknown cause. Seropositive patients had higher age at epilepsy onset and autoimmune comorbidity, but did not differ in other clinical, EEG or neuroimaging characteristics. Response to immunotherapy (seizure reduction &gt;50%) was observed in three of the six patients treated. CONCLUSIONS: Besides older age at epilepsy onset and autoimmune comorbidity, seropositive patients cannot be distinguished from seronegative patients on the basis of clinical, EEG or neuroimaging data. Copyright (C) 2018 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30103 - Neurosciences (including psychophysiology)

Project

—

Continuities

S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2018

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Seizure

ISSN

1059-1311

e-ISSN

—

Volume of the periodical

63

Issue of the periodical within the volume

December

Country of publishing house

GB - UNITED KINGDOM

Number of pages

6

Pages from-to

1-6

UT code for WoS article

000454963600001

EID of the result in the Scopus database

2-s2.0-85055344022